Central AsianResearch Index

Risk Factors for Post-COVID Conditions in QazVac-vaccinated Individuals: A Cross-sectional Study

Background: Although coronavirus disease 2019 (COVID-19) vaccination reduces severe acute disease, post-COVID-19 condition (PCC) remains a significant concern among vaccinated individuals. QazVac (QazCovid-in ® ), an inactivated whole-virion SARS-CoV-2 vaccine developed in Kazakhstan, has demonstrated efficacy against severe COVID-19; however, determinants of PCC following QazVac vaccination are not well characterized. This study aimed to identify demographic, clinical, and immunological factors associated with PCC among QazVac-vaccinated individuals. Materials and Methods: A cross-sectional study was conducted in Aktobe, Kazakhstan, including 90 QazVac-vaccinated individuals with PCC and 116 QazVac-vaccinated participants without PCC. Data on demographics, comorbidities, markers of acute COVID-19 severity, and immunological parameters (SARS-CoV-2 immunoglobulin G levels and lymphocyte subsets assessed by flow cytometry) were collected. Associations with PCC were examined using univariate and multivariable logistic regression analyses. Results: In the final multivariable model, polymerase chain reaction-confirmed SARS-CoV-2 infection was the strongest independent determinant of PCC (adjusted odds ratio [aOR] 28.8, 95% confidence interval [CI] 9.75–85.02; P < 0.001), whereas older age (aOR 1.04 per year, 95% CI 1.02–1.07; P = 0.002) and higher body mass index (BMI) (aOR 1.11 per kg/m², 95% CI 1.01–1.23; P = 0.036) remained independently associated. Chronic kidney disease (CKD) showed a strong but borderline association with PCC (aOR 5.87, 95% CI 0.98–35.05; P = 0.052), and sex was not independently associated after adjustment (men vs. women: aOR 0.49, 95% CI 0.20–1.17; P = 0.108). Conclusion: Despite QazVac vaccination, PCC occurs predominantly following breakthrough SARS-CoV-2 infection and is modified by age, BMI, and underlying CKD, alongside distinct humoral and cellular immune changes. These findings underscore the need for targeted postinfection monitoring in high-risk vaccinated individuals and support further investigation into immune mechanisms and vaccine strategies to mitigate long-term sequelae.

Сведения

Опубликовано
2025 · Т. 67, № 4, С. 391-403
Язык
Английский
ISSN
2707-6180 · 2707-6199
Издатель
Ovid Technologies (Wolters Kluwer Health)
Аффилиации
Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
Department of Internal Diseases 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
Department of Epidemiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan